Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results
March 22, 2022 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 22, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2022
March 10, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...
Cognition Therapeutics Announces Participation in March Investment Conferences
March 08, 2022 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...
Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics
February 08, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases,...
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
January 10, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease
January 04, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases,...
Cognition Therapeutics to Participate in Next-Generation Alzheimer’s Disease Panel at Virtual Biotech Showcase on January 11, 2022
December 21, 2021 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation
November 30, 2021 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights
November 18, 2021 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering
November 15, 2021 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...